Abstract
Article1 November 1963The Effect of Treatment in Patients with Chronic Myelogenous LeukemiaBiochemical StudiesJEROME B. BLOCK, M.D., PAUL P. CARBONE, M.D., JOOST J. OPPENHEIM, M.D., MIL FREI III, M.D.JEROME B. BLOCK, M.D.Search for more papers by this author, PAUL P. CARBONE, M.D.Search for more papers by this author, JOOST J. OPPENHEIM, M.D.Search for more papers by this author, MIL FREI III, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-59-5-629 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe circulating leukocytes of patients with chronic myelogenous leukemia (CML) have decreased or absent leukocyte alkaline phosphatase (LAP) activity (1-3). Recently, it has been shown that these leukocytes have a high intracellular hydrogen ion concentration (4, 5) and diminished leukocyte acid excretion when compared with leukocytes from patients without hematologic disease (5-7). The relative effects of several chemotherapeutic agents on the magnitude and duration of response of hematologic and cytogenetic abnormalities in patients with CML have been presented in the preceding paper by Carbone et al. (8) in this issue of the ANNALS. The present report describes the effects of...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
